key: cord-0868213-mbuu0jhn
authors: Ducloux, Didier; Colladant, Mathilde; Chabannes, Melchior; Yannaraki, Maria; Courivaud, Cécile
title: Humoral response after BNT162b2 mRNA COVID-19 vaccination in patients on haemodialysis depends on immune status
date: 2021-07-06
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab109
sha: b4bbd1ad760c42422714dddd0b4f7b41d86cb035
doc_id: 868213
cord_uid: mbuu0jhn

nan

responder patients had higher C reactive protein (CRP) concentrations (13.6 6 9.3 versus 5.7 6 3.9 mg/L; P ¼ 0.016) and lower lymphocyte count (1046 6 301 versus 1363 6 316/mm 2 ; P ¼ 0.031). There was a close inverse relationship between CRP concentration and antibody level (r ¼ À0.26; P ¼ 0.021). Other clinical and biological parameters were similar in responders and non-responders (Table 1) . Among previously exposed HD patients, we observed a stronger response to vaccine than that in naïve patients [5516 (895-40 000) versus 1837 (0-7459) UA/mL; P < 0.001).

We report in a single-centre study that 90% of dialysis patients have a vaccine response after two doses of BNT162b2 mRNA COVID-19 vaccine. We observe that the immune status markedly affects the vaccination response.

The dialysis population is heterogeneous. In this study, 30% of patients received or had received immunosuppressive drugs. Optimal response to vaccination in this group was only 53%, whereas it was 85% in those who did not take immunosuppressive drugs. Of note, a reduced response to BNT162b2 mRNA COVID-19 vaccine has been already reported in kidney transplant patients [6] . Exposure to such medications seems to be an important point to consider in the vaccination strategy.

HD patients exhibit both immune deficiency, which is similar to accelerated immune senescence, and inflammation, which is in part related to chronic innate immune activation [7, 8] . The term 'inflammaging' is frequently proposed to include these two aspects. We report that inflammaging characterized by low lymphocyte count and elevated CRP levels is associated Surprisingly, age was not associated with vaccination response. This may be explained by the low proportion of young patients. However, very old patients seem to have a similar response to patients in age range 50-70 years.

Patients with a history of COVID-19 infection have an explosive reaction after two doses of BNT162b2 mRNA COVID-19 vaccine. A single injection could be considered in these patients.

Two doses of BNT162b2 mRNA COVID-19 vaccine provide a strong humoral response in three-quarters of dialysis patients. The individual immune status seems to be more important to consider than the status of dialysed persons. 

COVID-19 in dialysis patients: outlasting and outsmarting a pandemic

Impaired immune responses and antigen-specific memory CD4þ T cells in hemodialysis patients

Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a hemodialysis cohort

Immunogenicity of SARS-CoV-2 vaccine in dialysis

Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)

Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients

Inflammation and premature ageing in chronic kidney disease

None declared.